
CARM1/HDAC2-IN-1

Cat. No.:	HY-157388	
Molecular Formula:	C ₃₅ H ₄₂ N ₈ O ₃	
Molecular Weight:	622.76	
Target:	HDAC; Histone Methyltransferase	
Pathway:	Cell Cycle/DNA Damage; Epigenetics	
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	



Product Data Sheet

BIOLOGICAL ACTIVITY				
Description	CARM1/HDAC2-IN-1 (compound CH-1) is a dual inhibitor against CARM1 and HDAC2, with IC ₅₀ values of 3.71 nM and 4.07 nM, respectively. CARM1/HDAC2-IN-1 possesses antitumor activity ^[1] .			
IC₅₀ & Target	CARM1 3.71 nM (IC ₅₀)	HDAC2 4.07 nM (IC ₅₀)		
In Vitro	CARM1/HDAC2-IN-1 inhibits proliferation of human prostate cancer cells DU145, RM1, LAPC4, 22RV1 and PC-3, with IC ₅₀ values of 0.09 μM , 0.71 μM , 0.68 μM, 0.95 μM and 0.43 μM, respectively ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation Assay ^[1]			
	Cell Line:	DU145, RM1, LAPC4, 22RV1 and PC-3		
	Concentration:	Ø1μM		
	Incubation Time:	72 h		
	Result:	Reduced proliferations of human prostate cancer cells.		
In Vivo	CARM1/HDAC2-IN-1 (i.p.; 0-20 mg/kg, injected every four days for six times) reveals an in vivo dose-dependent antitumor activity ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			

REFERENCES

[1]. Liang S, et al. Discovery and biological evaluation of novel CARM1/HDAC2 dual-targeting inhibitors with anti-prostate cancer agents. J Enzyme Inhib Med Chem. 2023 Dec;38(1):2241118.



Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA